TY - JOUR
T1 - Reasons why few patients with acute stroke receive tissue plasminogen activator
AU - Bambauer, Kara Z.
AU - Johnston, S. Claiborne
AU - Bambauer, Derek E.
AU - Zivin, Justin A.
PY - 2006/5
Y1 - 2006/5
N2 - Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.
AB - Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.
UR - http://www.scopus.com/inward/record.url?scp=33646411233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646411233&partnerID=8YFLogxK
U2 - 10.1001/archneur.63.5.661
DO - 10.1001/archneur.63.5.661
M3 - Review article
C2 - 16682535
AN - SCOPUS:33646411233
SN - 0003-9942
VL - 63
SP - 661
EP - 664
JO - Archives of Neurology
JF - Archives of Neurology
IS - 5
ER -